Dr. Jonathan Strosberg, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Js Weill Medical College, Cornell University (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 201
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Js Weill Medical College, Cornell University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME87326 -
Internal Medicine Physician
FL license ME87326
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- H Lee Moffitt Cancer Ctr and Res Inst Life Time Cancer Scrn Ctr Inc (1,178 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 201
- Services billed
- 489
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 202 | 156 |
| Established patient office or other outpatient visit, 30-39 minutes | 168 | 109 |
| New patient office or other outpatient visit, 60-74 minutes | 34 | 34 |
| Established patient office or other outpatient visit, 20-29 minutes | 28 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 44 payments worth $27,217 in total to this clinician.
| Merck Sharp & Dohme LLC | $8,845 |
|---|---|
| Exelixis Inc. | $6,396 |
| Genzyme Corporation | $4,206 |
| Tersera Therapeutics LLC | $3,541 |
| Delcath Systems | $1,661 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,155 |
| Ipsen Biopharmaceuticals, Inc | $448 |
| Curium US LLC | $442 |
| Consulting Fee | $16,820 |
|---|---|
| Honoraria | $4,420 |
| Travel and Lodging | $3,074 |
| Food and Beverage | $2,904 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 17, 2025 | Consulting Fee | $7,040 |
| Exelixis Inc. Jun 23, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $4,420 |
| Genzyme Corporation Jan 22, 2025 | Consulting Fee | $3,740 |
| Tersera Therapeutics LLC Oct 22, 2025 | Consulting Fee Xermelo · Oncology | $3,430 |
| Delcath Systems Nov 1, 2025 | Consulting Fee Hepzato Kit · Oncology | $1,500 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Consulting Fee | $1,110 |
| Merck Sharp & Dohme LLC Nov 5, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $616 |
| Exelixis Inc. May 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $487 |
| Exelixis Inc. May 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $417 |
| Genzyme Corporation Jan 22, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $352 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 17, 2025 | Consulting Fee | $7,040 |
| Merck Sharp & Dohme LLC Nov 17, 2025 | Travel and Lodging travel to Washington, DC | $150 |
| Merck Sharp & Dohme LLC Nov 6, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $234 |
| Merck Sharp & Dohme LLC Nov 6, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $229 |
| Merck Sharp & Dohme LLC Nov 6, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $123 |
| Merck Sharp & Dohme LLC Nov 5, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $616 |
| Merck Sharp & Dohme LLC Nov 5, 2025 | Travel and Lodging ONCOLOGY · travel to Herndon, VA · in-kind | $229 |
| Delcath Systems Nov 1, 2025 | Consulting Fee Hepzato Kit · Oncology | $1,500 |
| Tersera Therapeutics LLC Oct 22, 2025 | Consulting Fee Xermelo · Oncology | $3,430 |
| Exelixis Inc. Jun 23, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $4,420 |
| Exelixis Inc. May 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $487 |
| Exelixis Inc. May 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $417 |
| Exelixis Inc. May 29, 2025 | Travel and Lodging CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Chicago, IL · in-kind | $238 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 15, 2025 | Consulting Fee | $1,110 |
| Genzyme Corporation Jan 22, 2025 | Consulting Fee | $3,740 |
| Genzyme Corporation Jan 22, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $352 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 8 companies. The companies reported $939,487 in research payments for these studies, mostly to the institutions running them.
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05477576 - A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
Exelixis Inc. - DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patient…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOTE 158
Merck Sharp & Dohme LLC - A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Novartis Pharmaceuticals Corporation - DAREON-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patient…
Boehringer Ingelheim Pharma GmbH & Co.kg - Study name not reported
Organon Llc - Phase II study in SCLC and epNEC
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.